David Gaugh News Today

Here’s our list of the experts and advocates, outside the government, who are playing big roles in Washington’s policy debates.

The shortage of life-sustaining drugs for cancer, diabetes, and ADHD that has plagued hospitals and patients for years has now reached its peak with 323 medicines officially in short supply.

The Biosimilars Council released a new analysis by IQVIA that reveals a PBM strategy to protect $2 billion in profits by “strangling” the biosimilar market and preventing savings for patients.

An Avalere analysis found that fewer than half of all generic drugs are on generic formulary tiers.

The organization noted that the 1984 law has enabled trillions of dollars in savings, but the industry is at risk.

Laura Bray couldn't watch her 9-year-old's leukemia go untreated. She started campaigning to fix a broken system and get patients the treatments they need in the face of drug shortages.

Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and...

A report from the Association for Accessible Medicines (AAM) highlighted the value of biosimilars and generics, revealing that lower-cost versions of originator products accumulated $408 billion for the US health care system in 2022.

A total of 301 drugs were in active shortage last year

The main cause of the cancer drug shortage, experts agree, is the underlying weakness of the generic drug industry.